Filing Details

Accession Number:
0000899243-18-027481
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-10-25 18:28:40
Reporting Period:
2018-10-23
Accepted Time:
2018-10-25 18:28:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1664106 Logicbio Therapeutics Inc. LOGC () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1055951 Orbimed Advisors Llc 601 Lexington Avenue, 54Th Floor
New York NY 10022
Yes No Yes No
1682090 Orbimed Israel Gp Ii, L.p. 601 Lexington Avenue, 54Th Floor
New York NY 10022
Yes No Yes No
1682093 Ltd Ii Israel Advisors Orbimed 601 Lexington Avenue, 54Th Floor
New York NY 10022
Yes No Yes No
1682115 Orbimed Capital Gp Vi Llc 601 Lexington Avenue, 54Th Floor
New York NY 10022
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-10-23 2,997,760 $0.00 2,997,760 No 4 C Indirect See Footnotes
Common Stock Acquisiton 2018-10-23 2,279,023 $0.00 5,276,783 No 4 C Indirect See Footnotes
Common Stock Acquisiton 2018-10-23 490,000 $10.00 5,766,783 No 4 P Indirect See Footnotes
Common Stock Acquisiton 2018-10-23 700,000 $10.00 6,466,783 No 4 P Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnotes
No 4 C Indirect See Footnotes
No 4 P Indirect See Footnotes
No 4 P Indirect See Footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Convertible Preferred Stock Disposition 2018-10-23 2,678,571 $0.00 1,402,444 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2018-10-23 3,046,943 $0.00 1,595,316 $0.00
Common Stock Series B Convertible Preferred Stock Disposition 2018-10-23 4,352,775 $0.00 2,279,023 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
2,279,023 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. The total represents shares received upon conversion of Series A and Series B Convertible Preferred Stock.
  2. Upon closing of the Issuer's initial public offering, each share of Series A and Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series A or Series B Convertible Preferred Stock.
  3. The reportable securities are owned directly by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("OIP GP") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited ("OrbiMed Limited") is the managing member of OIP GP. By virtue of such relationships, OIP GP and OrbiMed Limited may be deemed to have voting and investment power over the securities held by OIP II and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Limited exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Erez Chimovits, a member of the Issuer's board of directors, is an employee of OrbiMed Limited.
  4. The reportable securities are owned directly by OrbiMed Private Investments VI ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VI and as a result may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein.
  5. This report on Form 4 is jointly filed by GP VI, OrbiMed Advisors, OIP GP and OrbiMed Limited. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.